CAMBRIDGE RESEARCH BIOCHEMICALS
Our core business is the chemical synthesis of peptides and the custom production of polyclonal antibodies.
Peptides and antibodies are different forms of proteins. As proteins control every process essential for life, discovering more about how they work and how they help the body fight disease and infection, is crucial for furthering medical research, drug development and health care provision.
All CRB’s products are used purely for medical research purposes — primarily drug discovery and disease research — either by commercial organisations or academic institutes. We do not sell them to be used directly on patients.
Alongside this custom-production, we also ‘partner’ small, highly specialised biochemical businesses to help them promote their services and gain wider exposure.
Canbex Therapeutics Ltd
Canbex Therapeutics is dedicated to treating spasticity in multiple sclerosis (MS) and other disorders. Spasticity is a debilitating and painful symptom that consists of involuntary spasms and stiffness of limbs and torso. The goal of the Canbex lead programme is to improve the lives of people with this serious and incurable disorder, and set a new standard in the treatment of spasticity.
The company’s lead compound, VSN16R, is currently in a Phase II study to determine its efficacy in relieving spasticity in people with MS. VSN16R was shown to be safe and well tolerated in a Phase I human safety trial in healthy volunteers that was completed in 2014.
Dr Jesse SchulmanCEO
Cell and Gene Therapy Catapult
The Cell Therapy Catapult was established in 2012 as a centre of excellence in innovation, with the core purpose of building a world-leading cell therapy industry in the UK. Supported by Innovate UK, our mission is to drive the growth of the industry by helping cell therapy organisations across the world translate early stage research into commercially viable and investable therapies.
Dr Almira BartolomeBD Europe
Dr Sarah MaxfieldBusiness Development
Censo Biotechnologies Ltd
Censo Biotechnologies Ltd is a stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking.
The company has the capabilities to generate induced pluripotent stem cells (iPSCs) from large cohorts of individuals and use the potential of these cells to create virtually any cell in the human body.
By developing cell-based models of disease using cells from a diverse range of tissue donors, the company supports the development of new targeted treatments for disease. Its major focus is the generation of novel data on drug efficacy and drug response variation for a given population.
Mr Aidan CourtneyChief Executive Officer
CIMYM BioSciences was established to develop oncology and immunological therapeutics. At CIMYM we believe passionately that drug development can only be successful if it is patient centred…’Begin with the patient in mind'. As a healthcare company we recognise an exceptional idea to fill a medical need, build a network and then establish a clinical utility that will improve patient care. CIMYM uses its expertise to manage value-enhancing activities in the development process of pharmaceuticals and diagnostics. It takes a patient-centred approach to co-develop these innovative products and in turn licenses the rights for manufacture and marketing to other pharmaceutical companies.
Clinical Network Services
Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA.
CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team.
BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.
With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies.
CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/regulatory approach to ensure value is strategically added at every stage of the product development life cycle.
Further information about CNS and its intelligent development services can be found at www.clinical.net.au
Crescendo Biologics Ltd
Crescendo has developed a novel antibody fragment platform which generates fully human VH products, the smallest antibody fragments, that mature in vivo in a transgenic mouse. The company has a highly experienced antibody drug discovery team and capability. Crescendo is using the platform to develop a portfolio of differentiated medicines, with an initial focus on novel topical products, and is identifying companies interested in partnering this platform.
Crystec applies the latest supercritical fluid (SCF) technology to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical and biopharmaceutical industries, contributing to human health by enabling new and more effective therapies. Crystec SCF technology can be applied to small and large drug molecules in a range of dosage forms. Our expertise includes designing the world’s first SCF engineered drug (Semprana – inhaled delivery for migraine), which is expected to launch later this year.
Our services include crystal form screening and particle design (including composite particles and scalable co-crystals), addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. Our process is scaled to GMP manufacturing levels.
We also have a strong product pipeline, focused on repurposing existing therapies. These assets are in a number of therapeutic areas including urge incontinence, women’s health, fungal infections, and malaria, and are currently available for out-licensing.
For more information on our technology or assets please visit www.crystecpharma.com or contact Catherine Hunter, Business Development Director (email@example.com).
Miss Catherine HunterBusiness Development Director
CTRL Group Ltd
New technologies have the potential to transform healthcare and medical research by increasing efficiency and creating more personalised medicine.
Ctrl Group is a team of designers, researchers, software developers and healthcare experts who work internationally with healthcare companies and providers who want to use new technology to improve people’s health. We create products and services that are effective, engaging and safe.